Media Summary: The recent US Food and Drug Administration Diana Aguiar de Sousa, MD, PhD, Central Lisbon University Hospital Center, Lisbon, Portugal, shares Juan Carlos Cardet MD MPH Associate Professor Division of Allergy & Immunology Department of Internal Medicine USF Health ...

Respiratory Research Update 29 May 2026 Jascayd Japan Approval Beam 302 Aatd Data And More - Detailed Analysis & Overview

The recent US Food and Drug Administration Diana Aguiar de Sousa, MD, PhD, Central Lisbon University Hospital Center, Lisbon, Portugal, shares Juan Carlos Cardet MD MPH Associate Professor Division of Allergy & Immunology Department of Internal Medicine USF Health ... A life-long treatment for high LDL, a VESALIUS subanalysis, tirzepatide beats semaglutide again, arrhythmia burden in cardiac ... This biweekly Gene and Cell Therapy video recap highlights regulatory activity, clinical progress, financing, commercial uptake, ... Live from AUA2025: Advances in ADT CME Available: ...

Shyam Prabhakaran, MD, MS, The University of Chicago, Chicago, IL, discusses Greetings, fellow investors! Welcome back to ShareTreck. RGX-202: Investigational Gene Therapy for Duchenne Muscular Dystrophy Pivotal

Photo Gallery

Respiratory Research Update – 29 May 2026: JASCAYD Japan Approval, BEAM-302 AATD Data and More
Trending in Respiratory: JASCAYD Japan Approval, BEAM-302 Data and more
Respiratory Research Update – 15 May 2026: MD-712 Filing, CXG87 NDA and More
Respiratory Research Update – 30 Apr 2026: ENFLONSIA EU Approval, Breztri Asthma Approval and More
How a New FDA Approval Could Change Progressive Pulmonary Fibrosis Care, With Shervin Assassi, MD
Updates on the management of tandem occlusions in AIS: the CASES trial and tirofiban
Beam Therapeutics Gets FDA RMAT for BEAM-302 | Gene Editing Breakthrough?
JASCAYD - FDA NDA approval - 2025-10-07
Biomarkers and Breakthroughs: Precision Approaches to Obstructive Airway Diseases in 2025
BEAM-302 Gets Orphan Drug Status | Beam’s AATD Therapy Explained
May 29 2026 This Week in Cardiology
Gene and Cell Therapy Update – 14 May 2026: CASGEVY, ATSN-201 Data and More
View Detailed Profile
Respiratory Research Update – 29 May 2026: JASCAYD Japan Approval, BEAM-302 AATD Data and More

Respiratory Research Update – 29 May 2026: JASCAYD Japan Approval, BEAM-302 AATD Data and More

This biweekly

Trending in Respiratory: JASCAYD Japan Approval, BEAM-302 Data and more

Trending in Respiratory: JASCAYD Japan Approval, BEAM-302 Data and more

This biweekly

Respiratory Research Update – 15 May 2026: MD-712 Filing, CXG87 NDA and More

Respiratory Research Update – 15 May 2026: MD-712 Filing, CXG87 NDA and More

This biweekly

Respiratory Research Update – 30 Apr 2026: ENFLONSIA EU Approval, Breztri Asthma Approval and More

Respiratory Research Update – 30 Apr 2026: ENFLONSIA EU Approval, Breztri Asthma Approval and More

This biweekly

How a New FDA Approval Could Change Progressive Pulmonary Fibrosis Care, With Shervin Assassi, MD

How a New FDA Approval Could Change Progressive Pulmonary Fibrosis Care, With Shervin Assassi, MD

The recent US Food and Drug Administration

Updates on the management of tandem occlusions in AIS: the CASES trial and tirofiban

Updates on the management of tandem occlusions in AIS: the CASES trial and tirofiban

Diana Aguiar de Sousa, MD, PhD, Central Lisbon University Hospital Center, Lisbon, Portugal, shares

Beam Therapeutics Gets FDA RMAT for BEAM-302 | Gene Editing Breakthrough?

Beam Therapeutics Gets FDA RMAT for BEAM-302 | Gene Editing Breakthrough?

Beam

JASCAYD - FDA NDA approval - 2025-10-07

JASCAYD - FDA NDA approval - 2025-10-07

This video describes the NDA

Biomarkers and Breakthroughs: Precision Approaches to Obstructive Airway Diseases in 2025

Biomarkers and Breakthroughs: Precision Approaches to Obstructive Airway Diseases in 2025

Juan Carlos Cardet MD MPH Associate Professor Division of Allergy & Immunology Department of Internal Medicine USF Health ...

BEAM-302 Gets Orphan Drug Status | Beam’s AATD Therapy Explained

BEAM-302 Gets Orphan Drug Status | Beam’s AATD Therapy Explained

Beam

May 29 2026 This Week in Cardiology

May 29 2026 This Week in Cardiology

A life-long treatment for high LDL, a VESALIUS subanalysis, tirzepatide beats semaglutide again, arrhythmia burden in cardiac ...

Gene and Cell Therapy Update – 14 May 2026: CASGEVY, ATSN-201 Data and More

Gene and Cell Therapy Update – 14 May 2026: CASGEVY, ATSN-201 Data and More

This biweekly Gene and Cell Therapy video recap highlights regulatory activity, clinical progress, financing, commercial uptake, ...

Live from AUA2025: Advances in ADT

Live from AUA2025: Advances in ADT

Live from AUA2025: Advances in ADT CME Available: ...

AHA/ASA 2026 guideline on acute ischemic stroke: updates regarding systems of care

AHA/ASA 2026 guideline on acute ischemic stroke: updates regarding systems of care

Shyam Prabhakaran, MD, MS, The University of Chicago, Chicago, IL, discusses

BEAM-302 Gets FDA Orphan Drug Status | Beam Therapeutics’ AATD Therapy Explained

BEAM-302 Gets FDA Orphan Drug Status | Beam Therapeutics’ AATD Therapy Explained

Greetings, fellow investors! Welcome back to ShareTreck.

Regenxbio Webinar May 2026

Regenxbio Webinar May 2026

RGX-202: Investigational Gene Therapy for Duchenne Muscular Dystrophy Pivotal

SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026

SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026

At ATS